Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A, B, C, A/E) / Gag (C) DNA and gp120 (A, B, C, A/E) Protein HIV-1 Vaccines (PDPHV) With Either Alhydrogel or GLA-SE in Healthy Adults Living Without HIV

NCT07675629 is registered in ClinicalTrials.gov with Worcester HIV Vaccine as lead sponsor.

NCT NCT07675629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07675629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A, B, C, A/E) / Gag (C) DNA and gp120 (A, B, C, A/E) Protein HIV-1 Vaccines (PDPHV) With Either Alhydrogel or GLA-SE in Healthy Adults Living Without HIV
Lead sponsor
Worcester HIV Vaccine
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
August 31, 2029
Enrollment
126 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv prevention